Moreover, given that G9a has been shown to be overexpressed in many tumor cells and is associated with the occurrence and development of tumors, it has become a promising antitumor target32, and many small molecule inhibitors of G9a have been developed for evaluation as cancer therapeutics. This evidence concerns the gene EHMT2 and neoplasm.